Open Access Opinion

SSA Positivity as Predictor of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder

Roberto Alejandro Cruz*1, Alexander B Ramos2, Bridget A Bagert3 and Jesus F Lovera4

1Dell Medical School, at the University of Texas, USA

2Louisiana Healthcare Science Center at New Orleans, USA

3Ochsner Clinic Foundation, New Orleans, USA

4Louisiana Healthcare Science Center at New Orleans, USA

Corresponding Author

Received Date: December 06, 2019;  Published Date: December 16, 2019


Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune astrocytopathy that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) [1]. This central nervous system (CNS) inflammatory syndrome has specific core clinical characteristics, three common presentations include optic neuritis that can be bilateral with more severe visual impairment as compared with patients with multiple sclerosis, longitudinal extensive transverse myelitis (LETM) typically involving three or more vertebral segments, and area postrema syndrome characterized by intractable hiccups and intractable nausea & vomiting.

Keywords: Neuromyelitis optica spectrum disorder; Devic’s disease; Sjogren’s syndrome; Autoimmune diseases; NMOSD

Signup for Newsletter
Scroll to Top